DWM
VRTX icon

Destination Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Destination Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$790K Buy
1,590
+38
+2% +$16.8K 0.02% 180
2026
Q1 		$693K Buy
1,552
+14
+0.9% +$6.53K 0.02% 178
2025
Q4 		$697K Sell
1,538
-104
-6% -$44.8K 0.02% 167
2025
Q3 		$643K Buy
1,642
+89
+6% +$37.2K 0.02% 158
2025
Q2 		$691K Sell
1,553
-1,724
-53% -$794K 0.02% 148
2025
Q1 		$1.59M Sell
3,277
-252
-7% -$117K 0.05% 116
2024
Q4 		$1.42M Buy
3,529
+168
+5% +$77.9K 0.04% 118
2024
Q3 		$1.56M Buy
3,361
+144
+4% +$69.2K 0.05% 117
2024
Q2 		$1.51M Buy
3,217
+17
+0.5% +$7.38K 0.05% 113
2024
Q1 		$1.34M Buy
3,200
+3
+0.1% +$1.27K 0.04% 120
2023
Q4 		$1.3M Buy
3,197
+107
+3% +$39.5K 0.05% 117
2023
Q3 		$1.07M Sell
3,090
-2
-0.1% -$699 0.04% 114
2023
Q2 		$1.09M Hold
3,092
– – 0.04% 115
2023
Q1 		$974K Sell
3,092
-100
-3% -$30K 0.04% 118
2022
Q4 		$922K Buy
3,192
+100
+3% +$30.5K 0.04% 120
2022
Q3 		$895K Hold
3,092
– – 0.04% 117
2022
Q2 		$871K Sell
3,092
-6
-0.2% -$1.61K 0.04% 121
2022
Q1 		$808K Buy
3,098
+11
+0.4% +$2.61K 0.03% 120
2021
Q4 		$678K Hold
3,087
– – 0.02% 128
2021
Q3 		$560K Sell
3,087
-44
-1% -$8.59K 0.02% 123
2021
Q2 		$631K Buy
3,131
+3
+0.1% +$628 0.02% 123
2021
Q1 		$672K Buy
3,128
+7
+0.2% +$1.54K 0.03% 118
2020
Q4 		$738K Buy
3,121
+23
+0.7% +$5.28K 0.03% 110
2020
Q3 		$843K Hold
3,098
– – 0.04% 99
2020
Q2 		$899K Sell
3,098
-347
-10% -$94.1K 0.05% 95
2020
Q1 		$820K Buy
+3,445
New +$790K 0.05% 104
2019
Q2 		– Sell
-17
Closed -$3K – 757
2019
Q1 		$3K Buy
+17
New +$3.14K ﹤0.01% 578

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Destination Wealth Management's VRTX Position: Q2 2026 in Review

Destination Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q2 2026, buying an estimated $16.8K and bringing the position to 1,590 shares worth $790K. The position accounts for 0.02% of the portfolio, ranked #180.

Destination Wealth Management first reported a position in VRTX in Q1 2019 and has held it in 27 quarters since. The position peaked at $1.59M in Q1 2025. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Destination Wealth Management held 1,590 shares of Vertex Pharmaceuticals worth $790K as of Q2 2026.
  • Destination Wealth Management bought 38 Vertex Pharmaceuticals shares in Q2 2026, an estimated $16.8K.
  • Vertex Pharmaceuticals made up 0.02% of Destination Wealth Management's portfolio in Q2 2026, its #180 holding.
  • Destination Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 27 quarters since.
  • Destination Wealth Management's Vertex Pharmaceuticals position peaked at $1.59M in Q1 2025.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Destination Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.